晚期非小细胞肺癌初治患者的直接非医疗成本分析  

Analysis of Direct Non-medical Cost of Newly Treated Advanced Non-small Cell Lung Cancer Patients

作　　者：李福明 夏宇[1,2] 魏艳 陈英耀[1,2] 杨毅[1,2] LI Fuming;XIA Yu;WEI Yan;CHEN Yingyao;YANG Yi(School of Public Health,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学公共卫生学院,上海200032 [2]国家卫生健康委员会卫生技术评估重点实验室(复旦大学),上海200032

出　　处：《卫生经济研究》2022年第10期58-61,共4页

基　　金：美国中华医学基金会“中国卫生技术评估示范项目”(Grant 19-318)。

摘　　要：目的:分析晚期非小细胞肺癌初治患者的直接非医疗成本及其影响因素,为相关部门提供对策建议。方法:对全国13家三级医疗机构中无EGFR/ALK突变的晚期NSCLC初治患者进行问卷调查,采用广义线性回归模型探索影响直接非医疗成本的相关因素。结果:晚期NSCLC初治患者平均病程6.5±8.4个月,直接非医疗成本9667.52元;综合医院就诊、病程越久、住院次数越多、每次住院天数越长的患者,直接非医疗成本越高。结论:我国晚期NSCLC初治患者直接非医疗负担较重,需要进一步采取有效措施减轻患者及其家庭的疾病经济负担,切实提高肿瘤医疗服务的可及性。Objective To understand the direct non-medical cost of newly treated patients with advanced non-small cell lung cancer(NSCLC)and its influencing factors,so that this paper could provide countermeasures and suggestions for relevant departments.Methods A questionnaire survey was conducted among first-line/newly diagnosed NSCLC patients without EGFR/ALK mutations in 13 tertiary medical institutions in China,and generalized linear regression model(GLM)was used to explore the relevant factors affecting direct non-medical costs of this population.Results The average duration of newly treated NSCLC was 6.5±8.4 months,and the average direct non-medical cost was 9667.52 yuan.Patients with visits in general hospitals,longer duration of disease,more times of hospitalization and more average days of hospitalization undertook more direct non-medical costs.Conclusion The direct non-medical burden of advanced NSCLC patients with first-line/newly diagnosed therapy is heavy.Further effective measures should be taken to reduce the economic burden of patients and their families,and improve the accessibility of cancer medical services.

关 键 词：晚期非小细胞肺癌 直接非医疗成本 疾病经济负担 

分 类 号：R195.4[医药卫生—卫生统计学]